ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events
Item 8.01 Other Events.
On January7, 2019, Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) issued a press release announcing that the Safety Review Committee (SRC) has endorsed dose escalation in the Company’s ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort, and that the SRC has also endorsed moving to the expansion phase of the Company’s ADP-A2M10 (MAGE-A10) lung cancer study. The press release is furnished as Exhibit99.1 to this report and is incorporated by reference herein.
The information in Item 8.01 of this Form8-K, including the attached Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.
Item 8.01 Financial Statements and Exhibits.
(d) Exhibits.
Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a19-1324_2ex99d1.htm EX-99.1 Exhibit 99.1 Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews PHILADELPHIA and OXFORD,…
To view the full exhibit click here
About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.
